Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer.

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

On Thursday, Aura Biosciences, Inc. AURA revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC).

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Franklin BSP Realty Trust Inc

Travelzoo

Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.

3 Small-Cap Stocks Ready to Deliver Significant Growth

APA Corporation

CuriosityStream

The 'Undercovered' Dozen series highlights 12 undercovered stocks to provide another source for investment ideas and to encourage community discussion. Qurate Retail's losses are mainly due to non-cash markdowns, making it a potential buy despite declining revenue and net income losses, according to Bashar Issa. RLJ Lodging Trust offers a 7.5% yield on their preferred stock, and Aristofanis Papadatos sees this as attractive for income-oriented investors as interest rates are expected to decline.

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +

Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy. Aura's financials are solid with a $499.53mn market cap and $187mn cash, providing a runway for its Phase 3 trial and additional studies.

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.

Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study

Thursday, Aura Biosciences, Inc. AURA revealed Phase 2 end-of-study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and ocular cancer.

Aura Biosciences Touts Promising Data From Eye Cancer Candidate

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders Today at 8:00 am ET BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced positive Phase 2 end of study results evaluating bel-sar (AU-011) for the first-line treatment of early-stage choroidal melanoma (CM), a vision and life-threatening ocular cancer.

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024 Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

The mean of analysts' price targets for Aura Biosciences (AURA) points to a 162.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET.

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET. To register, click here.

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D.

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights. “We're excited to expand bel-sar into bladder cancer, as we leverage our therapy's unique mechanism of action in additional solid cancer indicati.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

The average of price targets set by Wall Street analysts indicates a potential upside of 174.3% in Aura Biosciences, Inc. (AURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma. “Dosing of the first patient in this global Phase 3 trial is a major mileston.

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

The consensus price target hints at a 200.8% upside potential for Aura Biosciences, Inc. (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade

Results from the phase 1 trial, using bel-sar to treat patients with bladder cancer, expected in mid-2024. The global bladder cancer market is projected to reach $8.2 billion by 2032. Dosing of first patient in the phase 3 CoMpass trial, using bel-sar to treat patients with primary choroidal melanoma, expected in Q4 of 2023.

Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights. “In the third quarter we made meaningful progress across our portfolio,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura. “We are.

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share. The gross proceeds from the offering to Aura are expected to be $99.0 million, before deducting underwriting discounts and commission.

News for Aura Biosciences Stock (AURA)